

BODISEN BIOTECH, INC
Form 10-Q
September 11, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934

For the quarterly period ended: June 30, 2013

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934

For the transition period from _____ to _____

Commission File No. 000-32616

BODISEN BIOTECH, INC.
(Exact name of small business issuer as specified in its charter)

Delaware
(State or other jurisdiction of incorporation
or organization)

98-0381367
(I.R.S. Employer Identification No.)

Room 2001, FanMei Building
No. 1 Naguan Zhengjie
Xi'an, Shaanxi
People's Republic of China
(Address of Principal Executive Offices)

710068
(Zip Code)

852-2482-5168
(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer. ☐

Accelerated filer. ☐

Edgar Filing: BODISEN BIOTECH, INC - Form 10-Q

Non-accelerated filer. ☐ (Do not check if a smaller reporting company) ☒ Smaller reporting company.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒

The number of shares outstanding of each of the issuer's classes of common stock as of August 14, 2013: 21,510,250.

TABLE OF CONTENTS

		Page
	PART I	
<u>Item 1.</u>	<u>Financial Statements</u>	3
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operation</u>	16
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	21
<u>Item 4</u>	<u>Controls and Procedures</u>	21
	PART II	
<u>Item 1.</u>	<u>Legal Proceedings</u>	22
<u>Item 1A.</u>	<u>Risk Factors</u>	23
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	23
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	23
<u>Item 4.</u>	<u>Mine Safety Disclosures</u>	23
<u>Item 5.</u>	<u>Other Information</u>	23
<u>Item 6.</u>	<u>Exhibits</u>	23
<u>SIGNATURES</u>		24

Table of Contents

ITEM 1.

BODISEN BIOTECH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

	Notes	June 30, 2013 (unaudited)	December 31, 2012 (audited)
ASSETS			
CURRENT ASSETS:			
Cash		\$ 149,230	\$ 294,539
Accounts receivable, net of allowance for doubtful accounts of \$1,153,418 and \$475,122	3	1,705,873	3,584,676
Other receivables		26,546	3,963
Due from a related party	4	943,918	-
Inventory	5	1,506,643	2,166,992
Advances to suppliers	3	45,210	39,576
Prepaid expense and other current assets		19,198	4,391
Total current assets		4,396,618	6,094,137
PROPERTY AND EQUIPMENT, net	3	10,028,611	11,541,347
MARKETABLE SECURITY, AVAILABLE-FOR-SALE	6	211,952	282,603
INTANGIBLE ASSETS, net	7	4,818,883	4,776,979
TOTAL ASSETS		\$ 19,456,064	\$ 22,695,066
LIABILITIES AND STOCKHOLDERS' EQUITY			
CURRENT LIABILITIES:			
Accounts payable		\$ 367,854	\$ 532,266
Accrued expenses		67,249	76,984
Deferred revenue	3	645,631	753,616
Bank loan	8	-	1,426,500
Total current liabilities		1,080,734	2,789,366
Long-term bank loan		-	-
TOTAL LIABILITIES		1,080,734	2,789,366
STOCKHOLDERS' EQUITY:			
Preferred stock, \$0.0001 per share; authorized 5,000,000 shares; nil issued and outstanding		-	-
Common stock, \$0.0001 per share; 30,000,000 shares authorized and 21,510,250 shares issued and outstanding		2,151	2,151

Edgar Filing: BODISEN BIOTECH, INC - Form 10-Q

Additional paid-in capital		35,345,542	35,345,542
Accumulated other comprehensive income	3	11,293,591	10,973,725
Statutory reserve	11	4,314,488	4,314,488
Accumulated deficit		(32,580,442)	(30,730,206)
Total stockholders' equity		18,375,330	19,905,700
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		\$ 19,456,064	\$ 22,695,066

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND
OTHER COMPREHENSIVE INCOME (LOSS)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2013	2012	2013	2012
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
Revenue	\$682,357	\$1,428,557	\$934,221	\$2,509,523
Cost of revenue	473,786	1,138,190	698,252	1,890,532
Gross profit	208,571	290,367	235,969	618,991
Operating expenses				
Selling expenses	6,737	47,973	26,061	549,601
General and administrative expenses	1,098,398	1,320,993	1,597,978	2,139,602
Total operating expenses	1,105,135	1,368,966	1,624,039	2,689,203
Loss from operations	(896,564)	(1,078,599)	(1,388,070)	(2,070,212)
Non-operating income (expense):				
Other income (expense)	(405,519)	(1,676)	(405,755)	(2,288)
Interest income	77	385	359	20,761
Interest expense	(20,971)	(5,278)	(56,770)	(16,589)
Total non-operating income (expense)	(426,413)	(6,569)	(462,166)	1,884
Net loss	(1,322,977)	(1,085,168)	(1,850,236)	(2,068,328)
Other comprehensive loss				
Foreign currency translation gain	384,302	19,631	390,517	230,586
Unrealized gain (loss) on marketable equity security	(282,603)	(2,331,471)	(70,651)	60,558
Total other comprehensive income (loss)	101,699	(2,311,840)	319,866	291,144
Comprehensive loss	\$(1,221,278)	\$(3,397,008)	\$(1,530,370)	\$(1,777,184)
Weighted average shares outstanding :				
Basic	21,510,250	21,510,250	21,510,250	21,510,250
Diluted	21,510,250	21,510,250	21,510,250	21,510,250
Earnings (loss) per share:				
Basic	\$(0.06)	\$(0.05)	\$(0.09)	\$(0.10)
Diluted	\$(0.06)	\$(0.05)	\$(0.09)	\$(0.10)

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six Months Ended June 30,	
	2013	2012
	(unaudited)	(unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$(1,850,236)	\$(2,068,328)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Depreciation and amortization	561,483	849,434
Allowance for (recovery of) bad debts	661,793	(22,583)
Loss on disposal of equipment	414,176	-
(Increase) / decrease in assets:		
Accounts receivable	1,272,326	2,374,191
Other receivables	(22,279)	11,731
Inventory	698,490	(2,636,881)
Due from a related party	(934,584)	-
Advances to suppliers	(4,762)	(529,469)
Prepaid expense	(14,570)	(15,433)
Increase / (decrease) in current liabilities:		
Accounts payable	(173,544)	353,277
Accrued expenses	(28,956)	(27,647)
Deferred revenue	(122,452)	(239,607)
Other payables	17,949	7,625
Net cash provided by (used in) operating activities	474,834	(1,943,690)
CASH FLOWS FROM INVESTING ACTIVITIES		
Acquisition of property and equipment	-	(15,994)
Proceeds from sale of property and equipment	817,020	-
Proceeds from repayment of note receivable	-	1,425,501
Net cash provided by investing activities	817,020	1,409,507
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from bank loan	-	1,425,501
Repayment of bank loan	(1,441,800)	(1,425,501)
Net cash used in financing activities	(1,441,800)	-
Effect of exchange rate changes on cash and cash equivalents	4,637	6,550
NET DECREASE IN CASH	(145,309)	(527,633)
CASH, BEGINNING OF PERIOD	294,539	935,375

CASH, END OF PERIOD	\$ 149,230	\$ 407,742
---------------------	------------	------------

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Interest paid	\$56,770	16,589
Income taxes paid	\$-	\$-

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Note 1 - Organization and Basis of Presentation

The unaudited consolidated financial statements have been prepared by Bodisen Biotech, Inc., a Delaware corporation (the “Company” or “Bodisen”), pursuant to the rules and regulations of the Securities Exchange Commission (“SEC”). The information furnished herein reflects all adjustments (consisting of normal recurring accruals and adjustments) which are, in the opinion of management, necessary to fairly present the operating results for the respective periods. Certain information and footnote disclosures normally present in annual consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The results for the six months ended June 30, 2013 are not necessarily indicative of the results to be expected for the full year ending December 31, 2013.

Organization and Line of Business

The accompanying consolidated financial statements include the accounts of Bodisen Biotech, Inc., its 100% wholly-owned subsidiaries Bodisen Holdings, Inc. (BHI), Yang Ling Bodisen Agricultural Technology Co., Ltd (“Agricultural”), which was incorporated in March 2005, and Sinkiang Bodisen Agriculture Material Co., Ltd. (“Material”), which was incorporated in June 2006, as well as the accounts of Agricultural’s 100% wholly-owned subsidiary Yang Ling Bodisen Biology Science and Technology Development Company Limited (“BBST”). The Company is engaged in developing, manufacturing and selling organic fertilizers, liquid fertilizers, pesticides and insecticides in the People’s Republic of China and produces numerous proprietary product lines, from pesticides to crop-specific fertilizers. The Company markets and sells its products to distributors throughout the People's Republic of China, and these distributors, in turn, sell the products to farmers.

Note 2 – Going Concern

The accompanying unaudited consolidated financial statements have been prepared assuming the Company will continue as a going concern. As shown in the accompanying consolidated financial statements, the Company incurred a net loss of \$1,850,236 for the six months ended June 30, 2013 and had accumulated losses of \$32,580,442 at June 30, 2013. These create an uncertainty about the Company’s ability to continue as a going concern. In this regard, the Company’s Chairman has issued a letter of undertaking that he will provide financial support to the Company (Note 15). The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 3 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. All significant intercompany transactions and balances have been eliminated. The Company’s functional currency is the Chinese Yuan Renminbi (“RMB”); however the accompanying consolidated financial statements have been translated and presented in United States Dollars (\$) or (“USD”).

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Contingencies

Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company's management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company's legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. There were no contingencies of the type as of June 30, 2013 and December 31, 2012.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company's financial statements. If the assessment indicates that a potential material loss contingency is not probable but it is reasonably possible, or is probable but cannot be estimated, then the nature of the contingency liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. There were no contingencies of this type as of June 30, 2013 and December 31, 2012.

Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

Cash and Cash Equivalents

Cash and cash equivalents include cash on hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.

Accounts Receivable

The Company maintains reserves for potential credit losses for accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Reserves are recorded based on the Company's historical collection history. Allowance for doubtful accounts as of June 30, 2013 and December 31, 2012 were \$1,153,418 and \$475,122, respectively.

Advances to Suppliers

The Company advances to certain vendors for purchase of its materials. The advances to suppliers are interest free and unsecured.

Inventories

Inventories are valued at the lower of cost (determined on a weighted average basis) or market. The Management compares the cost of inventories with the market value and allowance is made for writing down their inventories to market value, if lower.

Property and Equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives of:

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Operating equipment	10 years
Vehicles	8 years
Office equipment	5 years
Buildings	30 years

The following are the details of the property and equipment at June 30, 2013 and December 31, 2012, respectively:

	June 30, 2013	December 31, 2012
Operating equipment	\$ 2,772,760	\$ 4,036,291
Vehicles	60,999	64,510
Office Equipment	7,017	7,594
Buildings	7,587,708	7,432,952
	10,428,484	11,541,347
Less accumulated depreciation	(399,873)	-
Property and equipment, net	\$ 10,028,611	\$ 11,541,347

Depreciation expense for the three and six months ended June 30, 2013 and 2012 was \$252,222 and \$504,498 and \$395,308 and \$793,093, respectively.

Impairment losses are required to be reflected as a permanent write-down of the cost basis of the affected assets. Accordingly, previously recorded depreciation on the impaired property and equipment (i.e. accumulated depreciation) has been eliminated as of December 31, 2012 which was the date of the impairment charge. Depreciation has since been recorded based on the new cost basis and the remaining estimated useful life of property and equipment from the beginning of January 1, 2013.

Marketable Securities

The Company applies the guidance of ASC Topic 320 "Investments-Debt and Equity Securities," which requires investments in equity securities to be classified as either trading securities or available-for-sale securities. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Marketable equity securities not classified as trading are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders' equity.

Long-Lived Assets

The Company applies the provisions of ASC Topic 360, "Property, Plant, and Equipment," which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted

cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. At June 30, 2013, there was no impairment of its long-lived assets. Based on its review at December 31, 2012, the Company took an impairment charge related to its property and equipment for \$9,057,267.

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Intangible Assets

Intangible assets consist of Rights to use land and Fertilizers proprietary technology rights. The Company follows ASC Topic 350 in accounting for intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets' carrying amounts. There were no impairment losses recorded on intangible assets for the three and six months ended June 30, 2013 and 2012 as the valuation report for the fair value of the land use rights exceeded the carrying value.

Fair Value of Financial Instruments

For certain of the Company's financial instruments, including cash and cash equivalents, accounts receivable, other receivables, advances to suppliers and accounts payable, the carrying amounts approximate their fair values due to their short maturities.

Fair Value Measurements

ASC Topic 820, "Fair Value Measurements and Disclosures," requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, "Financial Instruments," defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows:

- Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.
- Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
- Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following table represents our assets and liabilities by level measured at fair value on a recurring basis as of June 30, 2013 and December 31, 2012.

June 30, 2013	Level 1	Level 2	Level 3
Assets Description			
Marketable securities	\$ 211,952	\$ -	\$ -

December 31, 2012	Level 1	Level 2	Level 3
Assets Description			
	\$ 282,603	\$ -	\$ -

Marketable
securities

The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the consolidated balance sheets at fair value in accordance with ASC 825.

Revenue Recognition and Deferred Revenue

The Company's revenue recognition policies are in compliance with Staff accounting bulletin (SAB) 104. Because collection is not reasonably assured, sales revenue is recognized using the cost recovery method. Under the cost recovery method, no profit is recognized until collections exceed the cost of the goods sold. Profit not yet recognized is recorded as deferred revenue as a current liability.

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Advertising Costs

The Company expenses the cost of advertising as incurred or, as appropriate, the first time the advertising takes place. For the three and six months ended June 30, 2013, the Company incurred advertising expenses of \$0 and \$12,816, respectively. For the three and six months ended June 30, 2012, the Company incurred advertising expenses of \$12,149 and \$473,688, respectively.

Shipping and Handling Costs

Shipping and handling costs consist primarily of transportation charges for delivery of goods to customers and are included in selling, general and administrative expenses. The Company expenses all shipping cost when they are incurred. For the three and six months ended June 30, 2013, the Company incurred transportation charges of \$0 and \$0, respectively. For the three and six months ended June 30, 2012, the Company incurred transportation charges of \$20,587 and \$35,186, respectively.

Research and Development

The Company accounts for research and development costs in accordance with ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third party research and development costs are expensed when the contract work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.

Stock-Based Compensation

The Company records stock-based compensation in accordance with ASC Topic 718, "Compensation – Stock Compensation." ASC 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee's requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees. The Company recognizes in the statement of operations the fair value at the vesting date for stock options and other equity-based compensation issued to non-employees. There were no options outstanding as of June 30, 2013.

Income Taxes

The Company accounts for income taxes in accordance with ASC Topic 740, "Income Taxes." ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.

Foreign Currency Translation

The accounts of the Company’s Chinese subsidiaries are maintained in the RMB and the accounts of the U.S. parent company are maintained in the USD. The accounts of the Chinese subsidiaries are were translated into USD in accordance with Accounting Standards Codification (“ASC”) Topic 830 “Foreign Currency Matters,” with the RMB as the functional currency for the Chinese subsidiaries. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, “Comprehensive Income.” Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations.

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Foreign Currency Transactions and Comprehensive Income

Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company's Chinese subsidiaries is the Chinese Yuan Renminbi. Translation gains of \$11,364,242 and \$10,973,725 at June 30, 2013 and December 31, 2012, respectively are classified as an item of other comprehensive income in the stockholders' equity section of the consolidated balance sheet. During the three and six months ended June 30, 2013 and 2012 other comprehensive income in the consolidated statements of operations and other comprehensive income included translation gains of \$384,302 and \$390,517 and \$19,631 and \$230,586, and unrealized gain (loss) on marketable equity security of (\$282,603) and (\$70,651) and (\$2,331,471) and \$60,558, respectively. A detail of accumulated other comprehensive income is summarized below:

	Foreign Currency	Unrealized (loss)	Total Other Comprehensive Income
Balance, December 31, 2012	\$ 10,973,725	\$ -	\$ 10,973,725
Adjustments	390,517	(70,651)	319,866
Balance, June 30, 2013	\$ 11,364,242	\$ (70,651)	\$ 11,293,591

Basic and Diluted Earnings Per Share

Earnings per share is calculated in accordance with the ASC Topic 260, "Earnings Per Share." Basic earnings per share is based upon the weighted average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were no options as of June 30, 2013 and 2012 that were excluded from the diluted loss per share calculation due to their exercise price being greater than the Company's average stock price for the year.

Statement of Cash Flows

In accordance with ASC Topic 230, "Statement of Cash Flows," cash flows from the Company's operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.

Segment Reporting

ASC Topic 280, “Segment Report,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. ASC Topic 280 has no effect on the Company’s consolidated financial statements as the Company consists of one reportable business segment. All revenue is from customers in People’s Republic of China and all of the Company’s assets are located in People’s Republic of China.

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Recent Accounting Pronouncements

In February 2013, the FASB issued ASU No. 2013-02, which amends the authoritative accounting guidance under ASC Topic 220 “Comprehensive Income.” The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. However, the amendments require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under generally accepted accounting principles in the United States of America (“GAAP”) to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under GAAP that provide additional detail about those amounts. The amendments in this update are effective prospectively for reporting periods beginning after December 15, 2013. Early adoption is permitted. Adoption of this update is not expected to have a material effect on the Company’s consolidated results of operations or financial condition.

As of June 30, 2013, there are no recently issued accounting standards not yet adopted that would have a material effect on the Company’s financial statements.

Note 4 – Due From a Related Party

The Company had a receivable due from a related party. As of June 30, 2013 and December 31, 2012, the amount due from a related party was \$943,918 and \$0, respectively. The amount due is unsecured, non-interest bearing and is repayable on demand.

Note 5 – Inventory

Inventory at June 30, 2013 and December 31, 2012 consisted of the following:

	June 30, 2013	December 31, 2012
Raw materials	\$ 416,328	\$ 407,837
Packaging	86,879	85,343
Finished goods	1,003,436	1,673,812
	\$ 1,506,643	\$ 2,166,992

Note 6 – Marketable Security

During 2008, the Company exchanged \$3,291,264 of receivables for a 28.8% ownership interest in a Chinese company, Shanxi Jiali Pharmaceutical Co. Ltd (“Jiali”). The Company had written down the value of this investment by \$987,860 at December 31, 2008. This investment was originally accounted for under the equity method and the Company recorded equity income in this investment through September 30, 2009. During the fourth quarter of 2009,

Jiali was purchased by China Pediatric Pharmaceuticals, Inc. (“China Pediatric”), a public company. After the transaction, the Company owned 18.8% (or 2,018,590 shares) of China Pediatric. The Company then changed the accounting method for the investment from the equity method to the fair value method. At the date of the change, the investment was valued at \$2,829,732. As of June 30, 2013 and December 31, 2012, the fair value of the investment is \$211,952 and \$282,603, respectively, which is reflected in the consolidated balance sheet. The Company recognized an unrealized gain (loss) of (\$282,603) and (\$2,331,471) and (\$70,651) and \$60,558 for the three and six months ended June 30, 2013 and 2012, respectively, which is reflected in accumulated other comprehensive income in the consolidated statement of stockholder’s equity. At December 31, 2012, the Company determined that the decline in value of its investment in China Pediatric (a marketable equity security) was other-than-temporary resulting in the cumulative unrealized loss on this marketable equity security totaling \$2,774,742 being reclassified from accumulated other comprehensive income to retained earnings.

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Note 7– Intangible Assets

Net intangible assets at June 30, 2013 and December 31, 2012 were as follows:

	June 30, 2013	December 31, 2012
Rights to use land	\$ 5,613,681	\$ 5,406,639
Fertilizers proprietary technology rights	1,294,400	1,268,000
	6,908,081	6,674,639
Less accumulated amortization	(2,089,198)	(1,897,660)
Intangibles, net	\$ 4,818,883	\$ 4,776,979

The Company's office and manufacturing site is located in Yang Ling Agricultural High-Tech Industries Demonstration Zone in the province of Shaanxi, People's Republic of China. The Company leases land under a real estate contract with the Yang Ling Government of People's Republic of China for a period from November 2001 through November 2051. In accordance with the People's Republic of China's Governmental regulations, the Government owns all land.

During July 2003, the Company leased another parcel of land under a real estate contract with the Yang Ling government of the People's Republic of China for a period from July 2003 through June 2053.

The Company has recognized the amounts paid for the acquisition of rights to use land as intangible asset and amortizing over a period of fifty years.

The Company acquired Fluid and Compound Fertilizers proprietary technology rights on January 1, 2001 with a life ended December 31, 2011. The amortization of Fertilizers proprietary technology rights was over a period of ten years and was amortized in full during 2011.

On July 15, 2008, the Company entered into a 50 year land rights agreement.

Amortization expense for the Company's intangible assets amounted to \$28,943 and \$56,985 and \$28,845 and \$56,341 for the three and six months ended June 30, 2013 and 2012, respectively. Amortization of intangible assets for the next five years are as follows:

Year End	Amount
2013	57,554
2014	115,109
2015	115,109
2016	115,109
2017	115,109

Thereafter 4,300,893

\$ 4,818,883

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Note 8 – Bank Loan

During the quarter ended June 30, 2012, the Company obtained a bank loan for 9,000,000 RMB (approximately \$1,425,600). The loan bore a 9.84% annual interest rate, matured on May 27, 2013 and was secured by the Company's intangible assets in the nature of rights to use the land. The loan was repaid in full on its due date.

Note 9 – Stockholders Equity

Common stock

There was no stock based compensation incurred during the three and six months ended June 30, 2013.

Note 10 – Employee Welfare Plans

The Company has established its own employee welfare plan in accordance with Chinese law and regulations. The Company makes annual contributions of 14% of all employees' salaries to employee welfare plan. From January 1, 2007 onwards, no provision for employee welfare is allowed in accordance with the revised PRC regulations. The total expense for the above plan were \$0 for the three and six months ended June 30, 2013 and 2012. The Company has recorded welfare payable of \$0 at June 30, 2013 and December 31, 2012.

Note 11 – Statutory Common Welfare Fund

As stipulated by the Company Law of the People's Republic of China (PRC), net income after taxation can only be distributed as dividends after appropriation has been made for the following:

- i. Making up cumulative prior years' losses, if any;
- ii. Allocations to the "Statutory surplus reserve" of at least 10% of income after tax, as determined under PRC accounting rules and regulations, until the fund amounts to 50% of the Company's registered capital;
- iii. Allocations of 5-10% of income after tax, as determined under PRC accounting rules and regulations, to the Company's "Statutory common welfare fund", which is established for the purpose of providing employee facilities and other collective benefits to the Company's employees; and
- iv. Allocations to the discretionary surplus reserve, if approved in the stockholders' general meeting.

Pursuant to the new Corporate Law effective on January 1, 2006, there is now only one "Statutory surplus reserve" requirement. The reserve is 10 percent of income after tax, not to exceed 50 percent of registered capital.

The Company did not appropriate a reserve for the statutory surplus reserve and welfare fund for the three and six months ended June 30, 2013 and 2012.

Note 12 – Factory Location and Lease Commitments

The Company's principal executive offices are located in the Shaanxi province, People's Republic of China. BBST owns two factories, which includes three production lines, an office building, one warehouse, and two research labs and, is located on 10,900 square meters of land. The Company leases its office premises under an operating lease agreement that requires monthly rental payments of \$3,152 and the leases expire in 2018.

Future minimum lease payments under operating leases are as follows, by years as of June 30, 2013:

Year End	Amount
2013	18,912
2014	37,824
2015	37,824
2016	37,824
2017	37,824
2018	4,612
	\$ 174,820

Table of Contents

BODISEN BIOTECH, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2013
(UNAUDITED)

Note 13 – Current Vulnerability Due to Certain Concentrations

No vendor provided over 10% of the Company's raw materials for the six months ended June 30, 2013 and two vendors provided 17%, and 14% of the Company's raw materials for the six months ended June 30, 2012.

Four customers accounted for 35%, 22%, 20% and 13% of the Company's sales for the six months ended June 30, 2013. Two customers accounted for 30% and 14% of the Company's sales for the six months ended June 30, 2012.

The Company's operations are carried out in the PRC. Accordingly, the Company's business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, by the general state of the PRC's economy. The Company's business may be influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Note 14 – Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is, however, subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company's business. The Company is currently not aware of any such legal proceedings or claims that it believes would or could have, individually or in the aggregate, a material adverse affect on the Company's business, financial condition, results of operations or liquidity.

Note 15 – Chairman Financial Undertaking

On August 27, 2013, the Chairman of the Board issued an undertaking that he will give his every endeavor and effort to obtain necessary and adequate funding and recovery of amount due from a related party to meet the Company's financial obligations as when they are required thereby warranting that the manufacturing operations of the Company will not be affected. As of the date hereof no such funding has been needed by the Company. However, there can be no assurance that the Chairman will be successful in this undertaking.

Note 16 – Subsequent Events

Pursuant to ASC 855-10, the Company has evaluated all events or transactions that occurred from July 1, 2013, through the filing with the SEC. The Company did not have any material recognizable subsequent events during this period.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "continue," or the negative of such other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those listed under the heading "Risk Factors" and those listed in our other SEC filings. The following discussion should be read in conjunction with our Financial Statements and related notes thereto included elsewhere in this Quarterly Report. Throughout this Quarterly Report we will refer to Bodisen Biotech, Inc., together with its subsidiaries, as "Bodisen," the "Company," "we," "us," and "our."

Overview

We are incorporated under the laws of the state of Delaware and our operating subsidiary, Yang Ling, is headquartered in Shaanxi Province, the People's Republic of China. We are engaged in developing, manufacturing and selling organic fertilizers, liquid fertilizers, pesticides and insecticides in the People's Republic of China and produce numerous proprietary product lines, from pesticides to crop-specific fertilizers. We market and sell our products to distributors throughout the People's Republic of China, and these distributors, in turn, sell our products to farmers. We also conduct research and development to further improve existing products and develop new formulas and products.

Critical Accounting Policies and Estimates

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States ("US GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expenses amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

We believe the following is among the most critical accounting policies that impact our consolidated financial statements. We suggest that our significant accounting policies, as described in our condensed consolidated financial statements in the Summary of Significant Accounting Policies, be read in conjunction with this Management's Discussion and Analysis of Financial Condition and Results of Operations.

Accounts receivable

We maintain reserves for potential credit losses on accounts receivable and record them primarily on a specific identification basis. In order to establish reserves, we review the composition of accounts receivable and analyze

historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. This analysis and evaluation requires the use of judgments and estimates. Because of the nature of the evaluation, certain judgments and estimates are subject to change, which may require adjustments in future periods.

Table of Contents

Inventories

We value inventories at the lower of cost (determined on a weighted average basis) or market. When evaluating our inventory, we compare the cost with the market value and make allowance to write them down to market value, if lower. The determination of market value requires the use of estimates and judgment by our management.

Intangible assets

We evaluate intangible assets for impairment, at least on an annual basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. This evaluation requires the use of judgments and estimates, in particular with respect to recoverability. Recoverability of intangible assets, other long-lived assets and, goodwill is measured by comparing their net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss.

Revenue Recognition

Our revenue recognition policies are in compliance with Staff accounting bulletin (SAB) 104. Because collection is not reasonably assured, sales revenue is recognized using the cost recovery method. Under the cost recovery method, no profit is recognized until cash payments exceed the cost of the goods sold.

Recent Accounting Pronouncements

In February 2013, the FASB issued ASU No. 2013-02, which amends the authoritative accounting guidance under ASC Topic 220 "Comprehensive Income." The amendments do not change the current requirements for reporting net income or other comprehensive income in financial statements. However, the amendments require an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the statement where net income is presented or in the notes, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under generally accepted accounting principles in the United States ("GAAP") to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under GAAP that provide additional detail about those amounts. The amendments in this update are effective prospectively for reporting periods beginning after December 15, 2013. Early adoption is permitted. Adoption of this update is not expected to have a material effect on the Company's consolidated results of operations or financial condition.

Table of Contents

Results of Operations

Three Months Ended June 30, 2013 as Compared to Three Months Ended June 30, 2012

	Three Months Ended June 30,		Change	
	2013	2012	\$	%
Revenue	\$682,357	\$1,428,557	\$(746,200)	(52.2)
Cost of revenue	473,786	1,138,190	(664,404)	(58.4)
Gross profit	208,571	290,367	(81,796)	(28.2)
Operating expenses				
Selling expenses	6,737	47,973	(41,236)	(86.0)
General and administrative expenses	1,098,398	1,320,993	(222,595)	(16.9)
Total operating expenses	1,105,135	1,368,966	(263,831)	(19.3)
Loss from operations	(896,564)	(1,078,599)	182,035	(16.9)
Non-operating income (expense):				
Other income (expense)	(405,519)	(1,676)	(403,843)	24,095.6
Interest income	77	385	(308)	(80.0)
Interest expense	(20,971)	(5,278)	(15,693)	297.3
Total non-operating income(expense)	(426,413)	(6,569)	(419,844)	6,391.3
Net loss	\$(1,322,977)	\$(1,085,168)	\$(237,809)	21.9

Revenue: We generated revenue of \$682,357 for the three months ended June 30, 2013, a decrease of \$746,200 or 52.2%, compared to \$1,428,557 for the three months ended June 30, 2012. The decrease in revenue is primarily attributable to the Company's new products not receiving market acceptance by customers.

Gross Profit: We generated a gross profit of \$208,571 for the three months ended June 30, 2013, a decrease of \$81,796 or 28.2%, compared to \$290,367 for the three months ended June 30, 2012. Gross margin (gross profit as a percentage of revenue), was 30.6% for the three months ended June 30, 2013, compared to 20.3% for the three months ended June 30, 2012. The increase in the gross margin percentage was primarily attributable to the provision of deferred revenue under the cost recovery method which is affected by the timing of collections of our accounts receivable.

Selling Expenses: Aggregated selling expenses accounted for \$6,737 of our operating expenses for the three months ended June 30, 2013, a decrease of \$41,236 or 86.0%, compared to \$47,973 for the three months ended June 30, 2012. The decrease in our aggregated selling expense is primarily attributable to a decrease in advertising expenses.

General and Administrative Expenses: General and administrative expenses accounted for \$1,098,398 of our operating expenses for the three months ended June 30, 2013, a decrease of \$222,595 or 16.9%, compared to \$1,320,993 for the three months ended June 30, 2012. The decrease is principally due to the increase in our bad debt allowance of account receivable balance of approximately \$650,000 and a decrease in research and development

expenses of approximately \$960,000 during the three months ended June 30, 2013 compared to the three months ended June 30, 2012.

Non Operating Income and Expenses: We had total non-operating expenses of \$426,413 for the three months ended June 30, 2013, a change of \$419,844 compared to \$6,569 for the three months ended June 30, 2012. The change is principally due to:

- i. an increase in interest expense of \$15,693 (due to inception of new loan in June 2012) during the three months ended June 30, 2013 compared to the three months ended June 30, 2012.
- ii. an increase in loss on disposal of property and equipment of approximately \$415,000 during the three months ended June 30, 2013 compared to the three months ended June 30, 2012.

Table of Contents

Net loss: We had a net loss of \$1,322,977 for the three months ended June 30, 2013, a change of \$237,809 compared to \$1,085,168 for the three months ended June 30, 2012. The change is due to reasons described above, principally the decrease in revenue and increase in non-operating expense.

Six Months Ended June 30, 2013 as Compared to Six Months Ended June 30, 2012

	Six Months Ended June 30,		Change	
	2013	2012	\$	%
Revenue	\$934,221	\$2,509,523	\$(1,575,302)	(62.8)
Cost of revenue	698,252	1,890,532	(1,192,280)	(63.1)
Gross profit	235,969	618,991	(383,022)	(61.9)
Operating expenses				
Selling expenses	26,061	549,601	(523,540)	(95.3)
General and administrative expenses	1,597,978	2,139,602	(541,624)	(25.3)
Total operating expenses	1,624,039	2,689,203	(1,065,164)	(39.6)
Loss from operations	(1,388,070)	(2,070,212)	682,142	(33.0)
Non-operating income (expense):				
Other income (expense)	(405,755)	(2,288)	(403,467)	17,634.0
Interest income	359	20,761	(20,402)	(98.3)
Interest expense	(56,770)	(16,589)	(40,181)	242.2
Total non-operating income (expense)	(462,166)	1,884	(464,050)	(24,631.1)
Net loss	\$(1,850,236)	\$(2,068,328)	\$218,092	(10.5)

Revenue: We generated revenue of \$934,221 for the six months ended June 30, 2013, a decrease of \$1,575,302 or 62.8%, compared to \$2,509,523 for the six months ended June 30, 2012. The decrease in revenue is primarily attributable to the Company's new products not receiving market acceptance by customers.

Gross Profit: We generated a gross profit of \$235,969 for the six months ended June 30, 2013, a decrease of \$383,022 or 61.9%, compared to \$618,991 for the six months ended June 30, 2012. Gross margin (gross profit as a percentage of revenue), was 25.3% for the six months ended June 30, 2013, compared to 24.7% for the six months ended June 30, 2012. The increase in the gross margin was primarily attributable to the provision of deferred revenue under the cost recovery method which is affected by the timing of collections of our accounts receivable.

Selling Expenses: Aggregated selling expenses accounted for \$26,061 of our operating expenses for the six months ended June 30, 2013, a decrease of \$523,540 or 95.3%, compared to \$549,601 for the six months ended June 30, 2012. The decrease in our aggregated selling expense is primarily attributable to a decrease in advertising expenses.

General and Administrative Expenses: General and administrative expenses accounted for \$1,597,978 of our operating expenses for the six months ended June 30, 2013, a decrease of \$541,624 or 25.3%, compared to \$2,139,602 for the six months ended June 30, 2012. The decrease is principally due to the increase in our bad debt allowance of account receivable balance of approximately \$685,000 and a decrease in research and development expenses of approximately \$960,000 during the six months ended June 30, 2013 compared to the six months ended June 30, 2012.

Non Operating Income and Expenses: We had total non-operating expenses of \$462,166 for the six months ended June 30, 2013, a change of \$464,050 compared to income of \$1,884 for the six months ended June 30, 2012. The change is principally due to:

- i. a decrease in interest income of \$20,402 (due to full repayment of the note receivable in January 2012) during the six months ended June 30, 2013 compared to the six months ended June 30, 2012;

Table of Contents

- ii. an increase in interest expense of \$40,181 (due to inception of new loan in June 2012) during the six months ended June 30, 2013 compared to the six months ended June 30, 2012.
- iii. an increase in loss on disposal of property and equipment of approximately \$415,000 during the six months ended June 30, 2013 compared to the six months ended June 30, 2012.

Net loss: We had a net loss of \$1,850,236 for the six months ended June 30, 2013, a change of \$218,092 compared to \$2,068,328 for the six months ended June 30, 2012. The change is due to reasons described above, principally the decrease in revenue and increase in non-operating expense.

Liquidity and Capital Resources

We are primarily a parent holding company for the operations carried out by our operating subsidiary, Yang Ling, which carries out its activities in the People's Republic of China. Because of our holding company structure, our ability to meet our cash requirements apart from our financing activities, including payment of dividends on our common stock, if any, substantially depends upon the receipt of dividends from our subsidiaries, particularly Yang Ling.

As of June 30, 2013, we had \$149,230 of cash compared to \$294,539 as of December 31, 2012.

Cash balance decreased to \$145,309 as of June 30, 2013 as compared with \$294,539 as of December 31, 2012 due to repayment of bank loan and advance to a related party during the period. As of June 30, 2013, the Company therefore maintained an inventory of finished goods of \$1,003,436 in line with the Company's budgeted sales for the first half of 2013. This has a negative impact on the cash balance. On March 19, 2013, the chairman issued an undertaking that the chairman will give his every endeavor and best effort to obtain necessary and adequate funding to meet the Company's financial obligations as and when they are required thereby warranting that the manufacturing operations of the Company will not be affected.

While we have funded our operations since inception from operations and through private placements of equity securities and loans, there can be no assurance that adequate financing will continue to be available to us and, if available, on terms that are favorable to us.

We believe that we will require additional financing to carry out our intended objectives during the next twelve months. There can be no assurance, however, that such financing will be available or, if it is available, that we will be able to structure such financing on terms acceptable to us and that it will be sufficient to fund our cash requirements until we can reach a level of profitable operations and positive cash flows. If we are unable to obtain the financing necessary to support our operations, we may be unable to continue as a going concern. We currently have no firm commitments for any additional capital.

A downturn in the United States stock and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek alternative financing. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our shares of common stock or the debt securities may cause us to be subject to restrictive covenants. Even if we are able to raise the funds required, it is possible that we could incur unexpected

costs and expenses, fail to collect significant amounts owed to us, or experience unexpected cash requirements that would force us to seek additional financing. If additional financing is not available or is not available on acceptable terms, we will have to curtail our operations.

Cash Flows

Operating: We received \$474,834 of cash for operating activities for the six months ended June 30, 2013 compared to cash used of \$1,943,690 of cash used in operating activities for the six months ended June 30, 2012. The cash used in operating consisted of a net loss of \$1,850,236 offset by non cash expenses of depreciation and amortization of \$561,483, an increase in allowance for bad debts of \$661,793, loss on disposal of equipment of \$414,176 and due from a related party of \$934,584 and a decrease in accounts receivable of \$1,272,326 and inventory of \$698,490.

Table of Contents

Investing: Our investing activities for the six months ended June 30, 2013 provided cash of \$817,020 representing proceeds from sale of equipment \$817,020 for the six months ended June 30, 2013, compared to cash provided by investing activities of \$1,409,507 for the six months ended June 30, 2012 representing the addition of property and equipment from \$15,994 and proceeds from a note receivable of \$1,425,501 during this comparable period.

Financing. During the six months ended June 30, 2013, we used \$1,441,800 in financing activities by repaying our bank loan. During the six months ended June 30, 2012, we received and paid back \$1,425,501 in bank loans.

Off-Balance Sheet Arrangements

We currently do not have any material off-balance sheet arrangements except for the remaining pre-payments under the land-lease arrangement described above.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of our Disclosure Controls

Disclosure Controls and Procedures

Evaluation of our Disclosure Controls

As of the end of the period covered by this Quarterly Report on Form 10-Q, our principal executive officer and principal financial officer have evaluated the effectiveness of our “disclosure controls and procedures” (“Disclosure Controls”). Disclosure Controls, as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure Controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer as appropriate to allow timely decisions regarding required disclosure. Our management does not expect that our Disclosure Controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

During management’s assessment of the effectiveness of disclosure controls and procedures as of June 30, 2013, management identified deficiencies related to (i) the U.S. GAAP expertise of our internal accounting staff, (ii) a lack of segregation of duties within accounting functions, (iii) our internal risk assessment functions, and (iv) our communication functions.

A material weakness (within the meaning of PCAOB Auditing Standard No. 5) is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Table of Contents

In order to correct the foregoing deficiencies, we have taken the following remediation measures:

Although our accounting staff is professional and experienced in accounting requirements and procedures generally accepted in the PRC, management has determined that they require additional training and assistance in U.S. GAAP matters. Management has determined that our internal audit function is also significantly deficient due to insufficient qualified resources to perform internal audit functions. We retained an outside consulting firm in September 2006, which has since been assisting us in the implementation of Section 404.

We have committed to the establishment of effective internal audit functions and have instituted various anti-fraud control and financial and account management policies and procedures to strengthen our internal controls over financial reporting. Due to the scarcity of qualified candidates with extensive experience in U.S. GAAP reporting and accounting in the region, we were not able to hire sufficient internal audit resources before the end of June 2013. However, we will increase our search for qualified candidates with assistance from recruiters and through referrals.

Due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, we will implement procedures to assure that the initiation of transactions, the custody of assets and the recording of transactions will be performed by separate individuals.

As of the quarter ended June 30, 2013, we have not yet established an effective risk assessment system that enables us to collect related information comprehensively and systematically, assess risks in a timely, realistic manner, and take appropriate measures to control risks effectively. The Company is working with its outside consultant to devise an effective risk assessment system and our Chief Financial Officer Junyan Tong is responsible for overseeing such measures.

As of the quarter ended June 30, 2013, we are working to strengthen efforts to establish an effective communication system with clear procedures that will enable us to collect, process and deliver information related to internal controls in a timely fashion. Due to our limited staff, our Chief Financial Officer, Ms. Tong, will initially be primarily responsible for collecting and delivering such information among the different levels of Company management.

We believe that the foregoing steps will remediate the significant deficiency identified above, and we will continue to monitor the effectiveness of these steps and make any changes that our management deems appropriate.

Notwithstanding the conclusion that our internal control over financial reporting was not effective as of the end of the period covered by this report, the Chief Executive Officer and the Chief Financial Officer believe that the financial statements and other information contained in this quarterly report present fairly, in all material respects, our business, financial condition and results of operations. Nothing has come to the attention of management that causes them to believe that any material inaccuracies or errors exist in our financial statements as of June 30, 2013.

Changes in Internal Control over Financial Reporting

There were no changes in internal control over financial reporting (as defined in Rule 13a-15f under the Exchange Act) that occurred during the quarter ended June 30, 2013 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is, however, subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe would or could have, individually or in the aggregate, a material adverse affect on our business, financial condition, results of operations or liquidity.

Table of Contents

ITEM 1A. RISK FACTORS.

Not Applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable

ITEM 5. OTHER INFORMATION.

Not applicable.

ITEM 6. EXHIBITS.

Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K.

Exhibit No. Exhibit Description

<u>31.1</u>	<u>Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</u>
<u>31.2</u>	<u>Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</u>
<u>32.1</u>	<u>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
<u>32.2</u>	<u>Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101.INS	XBRL Instance Document*
101.SCH	XBRL Taxonomy Extension Schema Document*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB	XBRL Taxonomy Extension Label Linkbase Document*

101.PRE XBRL Taxonomy Extension Presentation Linkbase Document*

* Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

Table of Contents

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BODISEN BIOTECH, INC.

Dated: September 11, 2013

/s/ Lin Wang
Lin Wang
Chief Executive Officer and
President
(principal executive officer)

Dated: September 11, 2013

/s/ Junyan Tong
Junyan Tong
Chief Financial Officer
(principal financial officer and
accounting officer)